MENINGOCOCCAL DISEASE

If left untreated, meningococcal disease is fatal in approximately half of all cases.  Even with rapid and appropriate treatment, 5% to 10% of patients die, often within 24 to 48 hours of the onset of symptoms. As many as 20% of survivors experience long-term neurological effects such as brain damage, hearing loss, or learning disability. The bacteria is transmitted from person to person through droplets of respiratory or throat secretions, therefore, those living in close quarters, such as a college dormitory are at increased risk. Several vaccines are available and provide long-term protection against the disease.

Featured Articles

Yes Effectiveness of meningococcal serogroup C vaccine programmes
Ray Borrow, Raquel Abad, Caroline Trotter, et al

Since the introduction of monovalent meningococcal serogroup C (MenC) glycoconjugate (MCC) vaccines and the implementation of national vaccination...

No Timing of adolescent meningococcal conjugate vaccination: Attitudes and practices of pediatricians and family medicine physicians
Mandy A. Allison, Amanda C. Cohn, Shannon Stokley, et al

The meningococcal conjugate vaccine (MCV4) was recommended for those aged 11–18 years in 2005. Initial supply issues led to an emphasis on...

Yes Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: Results of an open-label, randomized, phase 3b controlled study in healthy infants
Arturo Abdelnour, Peter E. Silas, Marta Raquel Valdés Lamas, et al

The highest risk for invasive meningococcal disease (IMD) is in infants aged <1 year. Quadrivalent meningococcal conjugate vaccination has the...